
OLD Category: pan cancer panels
February 18, 2021 / J Immunother Cancer
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
February 17, 2021 / Oncoimmunology
Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers
February 12, 2021 / Cancer Immunol Immunother
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
February 12, 2021 / NPJ Precis Oncol
Clinical implications of systemic and local immune responses in human angiosarcoma
February 6, 2021 / Urol Oncol
Exploration of biomarkers from a pilot weight management study for men undergoing radical prostatectomy
February 4, 2021 / Mol Ther Oncolytics
Oncolytic vaccinia virus induces a novel phenotype of CD8+ effector T cells characterized by high ICOS expression
February 1, 2021 / Commun Biol
Kaiso (ZBTB33) subcellular partitioning functionally links LC3A/B, the tumor microenvironment, and breast cancer survival
January 28, 2021 / Cancer Immunol Res
Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance
January 26, 2021 / J Immunother Cancer
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist
January 25, 2021 / Nat Med